Rapid emergence of highly variable and transferable oxazolidinone and phenicol resistance gene optrA in German Enterococcus spp. clinical isolates

Enterococci are considered the 2nd to 3rd most common nosocomial pathogen causing life-threatening diseases amongst elderly and immunocompromised patients (https://www.ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-healthcare-associated-infections.pdf). The oxazolidinone linezolid represents one of the few remaining treatment options for infections caused by vancomycin-resistant enterococci (VRE) [1]. Shortly after the approval of linezolid in 2000 and following therapy, emergence of linezolid resistance has been reported for vancomycin-susceptible enterococci (VSE) and VRE [2, 3].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research